Posts tagged Mark Massaro
Canaccord ups OraSure price target to $18

Canaccord Genuity raised its price target for OraSure Technologies (NASDAQ:OSUR) to $18 from $15 after the company entered a four-year, up to $20-million agreement with the Bill & Melinda Gates Foundation, which will effectively subsidize the cost of the HIV self test.

Read More
Canaccord ups GenMark price target to $10.50

Canaccord Genuity has hiked its price target for GenMark Diagnostics (NASDAQ:GNMK) to $10.50 from $8. The stock closed at $9.27 on Wednesday.

After the close yesterday, GNMK announced a major milestone, achieving CE Mark for both its ePlex instrument and ePlex Respiratory Pathogen Panel, which was three weeks ahead of its recent timeline by the end of June.

Read More